Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".
Kikuchi T, Takeuchi Y, Nouso K, Kariyama K, Kuwaki K, Toshimori J, Iwado S, Moriya A, Hagihara H, Takabatake H, Tada T, Yasunaka T, Sakata M, Sue M, Miyake N, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A, Otsuka M. Kikuchi T, et al. Among authors: adachi t. Liver Int. 2024 May 8. doi: 10.1111/liv.15964. Online ahead of print. Liver Int. 2024. PMID: 38717049 No abstract available.
Evaluation of the advantage of surgeons certified by the endoscopic surgical skill qualification system participating in laparoscopic low anterior rectal resection.
Sawada N, Akagi T, Shimomura M, Todate Y, Nagakari K, Takeshita H, Maruyama S, Takata M, Ichikawa N, Hida K, Iijima H, Yamaguchi S, Taketomi A, Naitoh T; EnSSURE Study Group Collaboratives in Japan Society of Laparoscopic Colorectal Surgery.. Sawada N, et al. Ann Gastroenterol Surg. 2023 Dec 14;8(3):464-470. doi: 10.1002/ags3.12763. eCollection 2024 May. Ann Gastroenterol Surg. 2023. PMID: 38707236 Free PMC article.
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Nishimura K, Takahara K, Saruta M, Fujita K, Hashimoto M, Uemura H, Shiroki R, Azuma T, Kimura T, Ohno Y. Hirasawa Y, et al. Among authors: adachi t. J Cancer Res Clin Oncol. 2024 Apr 9;150(4):182. doi: 10.1007/s00432-024-05717-2. J Cancer Res Clin Oncol. 2024. PMID: 38592548 Free PMC article.
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Matsuda T, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: adachi t. Target Oncol. 2024 Mar 28. doi: 10.1007/s11523-024-01047-y. Online ahead of print. Target Oncol. 2024. PMID: 38546942
2,484 results